Literature DB >> 33390886

TLR4 Targeting as a Promising Therapeutic Strategy for Alzheimer Disease Treatment.

Yongji Zhou1, Yanxing Chen2, Congcong Xu3, Hao Zhang1, Caixiu Lin1.   

Abstract

Alzheimer disease (AD) is a devastating neurodegenerative disorder characterized by extracellular accumulation of amyloid-beta and formation of intracellular neurofibrillary tangles. Microglia activation and neuroinflammation play important roles in the pathogenesis of AD; Toll-like receptor 4 (TLR4)-a key component of the innate immune system-in microglia is also thought to be involved based on the observed association between TLR gene polymorphisms and AD risk. TLR4 has been shown to exert both detrimental and beneficial effects on AD-related pathologies. In preclinical models, experimental manipulations targeting TLR4 were shown to improve learning and memory, which was related to inhibition of pro-inflammatory cytokine release and reduction of oxidative stress. In this review, we summarize the key evidence supporting TLR4 as a promising therapeutic target in AD treatment.
Copyright © 2020 Zhou, Chen, Xu, Zhang and Lin.

Entities:  

Keywords:  Alzheimer’s disease; microglia; neuroinflammation; therapeutic target; toll-like receptor 4

Year:  2020        PMID: 33390886      PMCID: PMC7775514          DOI: 10.3389/fnins.2020.602508

Source DB:  PubMed          Journal:  Front Neurosci        ISSN: 1662-453X            Impact factor:   4.677


  12 in total

Review 1.  Microglia Phenotypes in Aging and Neurodegenerative Diseases.

Authors:  Menbere Y Wendimu; Shelley B Hooks
Journal:  Cells       Date:  2022-06-30       Impact factor: 7.666

Review 2.  Toll-like receptor-mediated neuroinflammation: relevance for cognitive dysfunctions.

Authors:  Silvia Squillace; Daniela Salvemini
Journal:  Trends Pharmacol Sci       Date:  2022-06-23       Impact factor: 17.638

Review 3.  APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer's disease pathology and brain diseases.

Authors:  Rosalía Fernández-Calle; Sabine C Konings; Javier Frontiñán-Rubio; Juan García-Revilla; Lluís Camprubí-Ferrer; Martina Svensson; Isak Martinson; Antonio Boza-Serrano; José Luís Venero; Henrietta M Nielsen; Gunnar K Gouras; Tomas Deierborg
Journal:  Mol Neurodegener       Date:  2022-09-24       Impact factor: 18.879

Review 4.  Microglial Inflammatory-Metabolic Pathways and Their Potential Therapeutic Implication in Major Depressive Disorder.

Authors:  Reza Rahimian; Claudia Belliveau; Rebecca Chen; Naguib Mechawar
Journal:  Front Psychiatry       Date:  2022-06-16       Impact factor: 5.435

Review 5.  PLCγ2 impacts microglia-related effectors revealing variants and pathways important in Alzheimer's disease.

Authors:  Ke Li; Beibei Ran; Yu Wang; Lulu Liu; Weidong Li
Journal:  Front Cell Dev Biol       Date:  2022-09-06

6.  Neuroprotective Effects of Phytochemicals against Aluminum Chloride-Induced Alzheimer's Disease through ApoE4/LRP1, Wnt3/β-Catenin/GSK3β, and TLR4/NLRP3 Pathways with Physical and Mental Activities in a Rat Model.

Authors:  Ahmed Mohsen Elsaid Hamdan; Fatimah Hussain J Alharthi; Ahmed Hadi Alanazi; Soad Z El-Emam; Sameh S Zaghlool; Kamel Metwally; Sana Abdulaziz Albalawi; Yahia S Abdu; Reda El-Sayed Mansour; Hoda A Salem; Zakaria Y Abd Elmageed; Karema Abu-Elfotuh
Journal:  Pharmaceuticals (Basel)       Date:  2022-08-17

Review 7.  Toll-Like Receptor 4: A Promising Therapeutic Target for Alzheimer's Disease.

Authors:  Linyu Wu; Xiaohui Xian; Guangyu Xu; Zixuan Tan; Fang Dong; Min Zhang; Feng Zhang
Journal:  Mediators Inflamm       Date:  2022-08-21       Impact factor: 4.529

Review 8.  Oligomeropathies, inflammation and prion protein binding.

Authors:  Gianluigi Forloni; Pietro La Vitola; Claudia Balducci
Journal:  Front Neurosci       Date:  2022-08-23       Impact factor: 5.152

9.  TPM1 mediates inflammation downstream of TREM2 via the PKA/CREB signaling pathway.

Authors:  Rong Li; Jing Zhang; Qiong Wang; Meng Cheng; Bin Lin
Journal:  J Neuroinflammation       Date:  2022-10-14       Impact factor: 9.587

Review 10.  Interleukin-17A in Alzheimer's Disease: Recent Advances and Controversies.

Authors:  Xin-Zhu Yan; Laijun Lai; Qiang Ao; Xiao-Hong Tian; Yan-Hui Zhang
Journal:  Curr Neuropharmacol       Date:  2022       Impact factor: 7.708

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.